Aytu Bioscience Inc operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Aytu Bioscience Inc with three other
companies in this sector in the United States:
Starpharma Holdings Limited
sales of $1.94 million
of which 100%
of which 48%
was New Drug Development), and
of which 93%
was Cancer Immunotherapy).
During the year ended June of 2019, sales at
Aytu Bioscience Inc were $7.32 million.
increase of 100.0%
versus 2018, when the company's sales were $3.66 million.
This was the fifth consecutive year of sales increases at Aytu Bioscience Inc
(and since 2014, sales have increased a total of 731,936%).